Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Bruntsch

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1984
Randomized phase II trial of carminomycin versus 4'-epidoxorubicin in advanced breast cancerM Rozencweig, W ten Bokkel Huinink, F Cavalli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 1996
Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive daysI Wolff, K Bench, J H Beijnen, et al.
European Journal of Cancer (Oxford, England : 1990)|August 26, 1998
Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: results of a phase II studyM Schuler, U Bruntsch, E Späth-Schwalbe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1994
Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer. EORTC Early Clinical Trials GroupJ Verweij, J Wanders, A L Nielsen, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials GroupU Bruntsch, B Heinrich, S B Kaye, et al.
BMJ (Clinical Research Ed.)|December 7, 1991
Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron?J F Smyth, R E Coleman, M Nicolson, et al.
Journal of Clinical Pharmacology|March 10, 2000
Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486A in phase I studies in patients with advanced cancersH Zhou, L Choi, H Lau, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 10, 1997
Comparison of three tropisetron-containing antiemetic regimens in the prophylaxis of acute and delayed chemotherapy-induced emesis and nauseaS Drechsler, U Bruntsch, J Eggert, et al.
Klinische Wochenschrift|June 15, 1982
A randomized study of combination chemotherapy (VAC-FMC) with or without immunostimulation by Corynebacterium parvum in metastatic breast cancerD Fritze, R Becher, B Massner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2000
Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. European Organization for Research and Treatment of Cancer Early Clinical Studies GroupF A Eskens, G A Greim, C van Zuylen, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1984
Randomized phase II trial of carminomycin versus 4'-epidoxorubicin in advanced breast cancerM Rozencweig, W ten Bokkel Huinink, F Cavalli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 1996
Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive daysI Wolff, K Bench, J H Beijnen, et al.
European Journal of Cancer (Oxford, England : 1990)|August 26, 1998
Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: results of a phase II studyM Schuler, U Bruntsch, E Späth-Schwalbe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1994
Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer. EORTC Early Clinical Trials GroupJ Verweij, J Wanders, A L Nielsen, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials GroupU Bruntsch, B Heinrich, S B Kaye, et al.
BMJ (Clinical Research Ed.)|December 7, 1991
Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron?J F Smyth, R E Coleman, M Nicolson, et al.
Journal of Clinical Pharmacology|March 10, 2000
Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486A in phase I studies in patients with advanced cancersH Zhou, L Choi, H Lau, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 10, 1997
Comparison of three tropisetron-containing antiemetic regimens in the prophylaxis of acute and delayed chemotherapy-induced emesis and nauseaS Drechsler, U Bruntsch, J Eggert, et al.
Klinische Wochenschrift|June 15, 1982
A randomized study of combination chemotherapy (VAC-FMC) with or without immunostimulation by Corynebacterium parvum in metastatic breast cancerD Fritze, R Becher, B Massner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2000
Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. European Organization for Research and Treatment of Cancer Early Clinical Studies GroupF A Eskens, G A Greim, C van Zuylen, et al.
Pageof 10